May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Erythropoietin and Vascular Endothelial Growth Factor in the Vitreous Fluid of Patients with Various Vitreoretinal Diseases
Author Affiliations & Notes
  • E. Takahashi
    Ophthalmology, Kumamoto Univ Sch Med, Kumamoto City, Japan
  • A. Hirata
    Ophthalmology, Kumamoto Univ Sch Med, Kumamoto City, Japan
  • Y. Inomata
    Ophthalmology, Kumamoto Univ Sch Med, Kumamoto City, Japan
  • T. Kawaji
    Ophthalmology, Kumamoto Univ Sch Med, Kumamoto City, Japan
  • M. Fukushima
    Ophthalmology, Kumamoto Univ Sch Med, Kumamoto City, Japan
  • H. Tanihara
    Ophthalmology, Kumamoto Univ Sch Med, Kumamoto City, Japan
  • Footnotes
    Commercial Relationships  E. Takahashi, None; A. Hirata, None; Y. Inomata, None; T. Kawaji, None; M. Fukushima, None; H. Tanihara, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 4870. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      E. Takahashi, A. Hirata, Y. Inomata, T. Kawaji, M. Fukushima, H. Tanihara; Erythropoietin and Vascular Endothelial Growth Factor in the Vitreous Fluid of Patients with Various Vitreoretinal Diseases . Invest. Ophthalmol. Vis. Sci. 2003;44(13):4870.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Erythropoietin (EPO) is known to protect neurons against ischemia and oxidative stress. Both EPO and vascular endothelial growth factor (VEGF) are upregulated by hypoxia-inducible factor (HIF-1). The purpose of this study is to investigate the concentration of EPO in the vitreous fluid of various vitreoretinal diseases and the association VEGF. Methods: Vitreous fluid samples were collected during vitreous surgery from 13 patients with proliferative diabetic retinopathy (PDR), 13 patients with macular edema due to retinal vein occulusion (BRVO), and 13 patients with idiopathic macular hole (MH). EPO levels were determined by using radioimmunoassay and VEGF levels were assessed by ELISA. Serum samples were obtained and assessed from 10 patients with PDR, 11 patients with BRVO and 9 patients with MH prior to vitreous surgery. Results: The intravitreal concentration of EPO was significantly higher in eyes with PDR (1128.3 ± 1070.7 mU/ml, mean ± standard deviation), in eyes with BRVO (333.0 ± 460.4 mU/ml) than in eyes with MH (33.9 ± 17.8 mU/ml) (P=0.002, P=0.035, respectively). The vitreous concentration of VEGF was also significantly higher in eyes with PDR (1530 ± 2970 pg/ml), in eyes with BRVO (895±1041 pg/ml) than in eyes with MH (18±2 pg/ml )(P<0.001,P=0.008 respectively). However, there was no correlation between EPO and VEGF in vitreous concentration of all groups. Serum concentrations of EPO and VEGF did not show any statistically significant differences among three groups. Conclusions: EPO and VEGF were upregulated in ischemic retinal diseases, such as PDR and BRVO, although they are not related. Serum diffusion may play a partial role in explaining no correlation between EPO and VEGF.

Keywords: cytokines/chemokines • vascular occlusion/vascular occlusive disease • vitreous 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×